Only a few days to go: We’re raising £25,000 to keep TheyWorkForYou running and make sure people across the UK can hold their elected representatives to account.

Donate to our crowdfunder

Ibrutinib

Department of Health and Social Care written question – answered on 25th July 2018.

Alert me about debates like this

Photo of Lord Touhig Lord Touhig Labour

To ask Her Majesty's Government, further to the reply by Lord O'Shaughnessy on 7 June (HL Deb, col 1405), what was the outcome of his meeting with patients' groups regarding the use of Ibrutinib in England.

Photo of Lord O'Shaughnessy Lord O'Shaughnessy The Parliamentary Under-Secretary for Health and Social Care

On 22 May I met with the Chronic Lymphocytic Leukaemia Association, and Lord Forsyth regarding the use of ibrutinib in England. Following this meeting, I met with NHS England and the National Institute of Health and Care Excellence to discuss the treatment criteria set by NHS England for ibrutinib. As a result, NHS England committed to receiving, and reviewing by the end of July, any further evidence that patients and clinicians wish to submit on this matter and will review the criteria in light of all evidence submitted.

Does this answer the above question?

Yes0 people think so

No0 people think not

Would you like to ask a question like this yourself? Use our Freedom of Information site.